{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-027293","form_type":"8-K","ticker":"CLRB","cik":"0001279704","company_name":"Cellectar Biosciences, Inc.","filed_at":"2022-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.762897+00:00","generated_at":"2026-06-27T04:04:04.676095+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cellectar Biosciences names Chad Kolean CFO, promotes Jarrod Longcor to COO","bullets":["CFO Dov Elefant resigned Feb 22, 2022; Chad Kolean rejoined as CFO same day, previously served as CFO 2014-2017.","Kolean receives $340K base salary, 40% target bonus, and 150,000-share option (3-yr vest) as inducement grant.","Jarrod Longcor promoted to COO from Chief Business Officer; he has been with the company for 6 years.","Option exercise price equals Feb 22, 2022 closing price; Kolean eligible for annual equity awards under 2021 plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-027293","json":"https://secwatch.observer/filing/0001104659-22-027293.json","markdown":"https://secwatch.observer/filing/0001104659-22-027293.md","text":"https://secwatch.observer/filing/0001104659-22-027293.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465922027293/0001104659-22-027293-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465922027293/tm227716d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T04:04:04.676095+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0ee06d13a2","claim":"Jarrod Longcor changed role as Chief Operating Officer at Cellectar Biosciences, Inc..","evidence_excerpt":"On February 22, 2022, Jarrod Longcor, age 48, was promoted to the Company’s Chief Operating Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465922027293/0001104659-22-027293-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"47eb2f1c05","claim":"Dov Elefant resigned as Chief Financial Officer at Cellectar Biosciences, Inc..","evidence_excerpt":"On February 22, 2022, Dov Elefant, the Chief Financial Officer of Cellectar Biosciences, Inc. (the “Company”), resigned from his office effective February 22, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465922027293/0001104659-22-027293-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"b1426b81d6","claim":"Chad Kolean was appointed as Chief Financial Officer at Cellectar Biosciences, Inc..","evidence_excerpt":"On February 22, 2022, Chad Kolean, age 57, rejoined the Company as its Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465922027293/0001104659-22-027293-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"rejoined"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}